Replies to post #34311 on Marker Therapeutics Inc (MRKR)

[bar1080]

Revolving door execs -- especially CFOs -- are a time honored pennyland technique. Hard to blame the CFO for some shortcoming if a company has a new CFO every few months and many are called "Interim."

I always check out the main financial officer first, his education, his firm and whether he's a CPA or just some bookkeeper, or not even that. Actually I tend to read SEC filings backwards starting with the financial certifications at the document's end. I'll usually pass on any stock without a "Big Four" signing off. I recommend that others do too.

There's a damn good reason Big Fours audit about 99+% of NYSE firms. The costs are insignificant compared with the benefits.

[microcapbiotech]

Howdy PL, Yes I thought it was strange that Lurieu leaving on Nov. 17 but yet the contract ends Jan. 16.
The only thing I could think of was: MRKR didn't like Lurier as CFO but couldn't just end the whole contract without some big penalty, so they agreed to just ditch the CFO part (to Juan) and let Danforth continue with the rest of the stuff like HR and then end the contract as a whole in Jan..
I do not like strange unexplained stuff, I will continue to give Juan the benefit of the doubt until he just really screws something up and turns into Peter Hoang, but I hope that does not happen.
THANKS